Gene therapy for mesothelioma and lung cancer

American Journal of Respiratory Cell and Molecular Biology

Volumn 42, Issue 4, 2010, Pages 385-393

  Vachani, Anil ^a   Moon, Edmund ^a   Wakeam, Elliot ^a   Albelda, Steven M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; BETA INTERFERON; COMPLEMENTARY RNA; CYTOKINE; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; LENTIVIRUS VECTOR; MUCIN 1; RETROVIRUS VECTOR; VIRUS VECTOR; CANCER VACCINE;

ADENO ASSOCIATED VIRUS; ADOPTIVE TRANSFER; ADVANCED CANCER; APOPTOSIS; CANCER GENE THERAPY; CYTOKINE PRODUCTION; DISEASE COURSE; GENE EXPRESSION; GENE THERAPY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LUNG CANCER; MESOTHELIOMA; PLEURA MESOTHELIOMA; PROGNOSIS; REVIEW; SUICIDE GENE; TUMOR IMMUNOLOGY; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CLINICAL TRIAL; GENE VECTOR; GENETICS; IMMUNOLOGY; LUNG TUMOR; METHODOLOGY; PLEURA TUMOR; SUICIDE TRANSGENE; VIRUS;

ADOPTIVE TRANSFER; ANIMALS; APOPTOSIS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; CYTOKINES; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS; PROGNOSIS; RNA, ANTISENSE; VIRUSES;

EID: 77950482352     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2010-0026RT     Document Type: Review

References (66)

1. Fischer A, Cavazzana-Calvo M. Gene therapy of inherited diseases. Lancet 2008;371:2044-2047.
2. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-2248.
3. Hwang HC, Smythe WR, Elshami AA, Kucharczuk JC, Amin KM, Williams JP, Litzky LA, Kaiser LR, Albelda SM. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995;13:7-16.
4. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006; 208:299-318.
5. Bachtarzi H, Stevenson M, Fisher K. Cancer gene therapy with targeted adenoviruses. Expert Opin Drug Deliv 2008;5:1231-1240.
6. Douglas JT. Adenoviral vectors for gene therapy. Mol Biotechnol 2007;36:71-80.
7. Breckpot K, Emeagi PU, Thielemans K. Lentiviral vectors for antitumor immunotherapy. Curr Gene Ther 2008;8:438-448.
8. Schambach A, Baum C. Clinical application of lentiviral vectors: concepts and practice. Curr Gene Ther 2008;8:474-482.
9. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008;21:583-593.
10. Schultz BR, Chamberlain JS. Recombinant adeno-associated virus transduction and integration. Mol Ther 2008;16:1189-1199.
11. Garber DA, O'Mara LA, Zhao J, Gangadhara S, An I, Feinberg MB. Expanding the repertoire of modified vaccinia ankara-based vaccine vectors via genetic complementation strategies. PLoS One 2009;4:e5445.
12. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009;9:64-71.
13. Chesnoy S, Huang L. Structure and function of lipid-DNA complexes for gene delivery. Annu Rev Biophys Biomol Struct 2000;29:27-47.
14. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002;9:1647-1652.
15. Tiberghien P. Use of suicide genes in gene therapy. J Leukoc Biol 1994;56:203-209. (Pubitemid 24270503)
16. Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 1988;10:S490-S494.
17. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, Recio A, Knox L, Wilson JM, Albelda SM, et al. Adenovirusmediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998;9:1083-1092.
18. Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P, Amin KM, Litzky LA, Wilson JM, Kaiser LR, et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005;11:7444-7453.
19. Harrison LH Jr, Schwarzenberger PO, Byrne PS, Marrogi AJ, Kolls JK, McCarthy KE. Gene-modified pa1-stk cells home to tumor sites in patients with malignant pleural mesothelioma. Ann Thorac Surg 2000;70:407-411.
20. Mukherjee S, Haenel T, Himbeck R, Scott B, Ramshaw I, Lake RA, Harnett G, Phillips P, Morey S, Smith D, et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther 2000;7:663-670.
21. Pitako J, Squiban P, Acres B, Digel W. A randomized phase II single center study of gene transfer-based non-specific immunotherapy of malignant mesothelioma (MM) by intratumoral injections of an interleukin-2 producing vero cells [abstract]. Proc American Society Clinical Oncology 2003:920.
22. Tan Y, Xu M, Wang W, Zhang F, Li D, Xu X, Gu J, Hoffman RM. IL-2 gene therapy of advanced lung cancer patients. Anticancer Res 1996;16:1993-1998. (Pubitemid 26270714)
23. Odaka M, Sterman DH, Wiewrodt R, Zhang Y, Kiefer M, Amin KM, Gao GP, Wilson JM, Barsoum J, Kaiser LR, et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferonbeta gene therapy is attributable to induction of systemic immunity. Cancer Res 2001;61:6201-6212. (Pubitemid 32762558)
24. Odaka M, Wiewrodt R, DeLong P, Tanaka T, Zhang Y, Kaiser L, Albelda S. Analysis of the immunologic response generated by Ad.IFN-beta during successful intraperitoneal tumor gene therapy. Mol Ther 2002;6:210-218.
25. Sterman DH, Gillespie CT, Carroll RG, Coughlin CM, Lord EM, Sun J, Haas A, Recio A, Kaiser LR, Coukos G, et al. Interferon beta adenoviral gene therapy in a patient with ovarian cancer. Nat Clin Pract Oncol 2006;3:633-639.
26. Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, Kapoor V, Sun J, Hodinka R, Brown JL, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007;13:4456-4466.
27. Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT, Cheng G, Sun J, Moon E, Pereira L, et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther (In press)
28. Lambright ES, Force SD, Lanuti ME, Wasfi DS, Amin KM, Albelda SM, Kaiser LR. Efficacy of repeated adenoviral suicide gene therapy in a localized murine tumor model. Ann Thorac Surg 2000;70:1865-1870; discussion 1870-11861
29. Kruklitis RJ, Singhal S, Delong P, Kapoor V, Sterman DH, Kaiser LR, Albelda SM. Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg 2004;127:123-130.
30. Dong M, Li X, Hong LJ, Xie R, Zhao HL, Li K, Wang HH, Shin WD, Shen HJ. Advanced malignant pleural or peritoneal effusion in patients treated with recombinant adenovirus p53 injection plus cisplatin. J Int Med Res 2008;36:1273-1278.
31. Zhao WZ, Wang JK, Li W, Zhang XL. Clinical research on recombinant human ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer. Chin J Cancer 2009;28:1324-1327.
32. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996;2:985-991.
33. Schuler M, Rochlitz C, Horowitz JA, Schlegel J, Perruchoud AP, Kommoss F, Bolliger CT, Kauczor HU, Dalquen P, Fritz MA, et al. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 1998;9:2075-2082. (Pubitemid 28463925)
34. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:763-771.
35. Fujiwara T, Tanaka N, Kanazawa S, Ohtani S, Saijo Y, Nukiwa T, Yoshimura K, Sato T, Eto Y, Chada S, et al. Multicenter phase i study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2006;24:1689-1699.
36. Weill D, Mack M, Roth J, Swisher S, Proksch S, Merritt J, Nemunaitis J. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. Chest 2000;118:966-970.
37. Nemunaitis J, Swisher SG, Timmons T, ConnorsD, MackM,Doerksen L, Weill D,Wait J, Lawrence DD, Kemp BL, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000;18:609-622.
38. Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ, Laufman L, Gralla R, Kuball J, Buhl R, et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001;19:1750-1758.
39. Keedy V, Wang W, Schiller J, Chada S, Slovis B, Coffee K, Worrell J, Thet LA, Johnson DH, Carbone DP. Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597. J Clin Oncol 2008;26:4166-4171.
40. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005;16:1016-1027.
41. Ji L, Roth JA. Tumor suppressor fus1 signaling pathway. J Thorac Oncol 2008;3:327-330.
42. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon G, Janssen W, Lee JH, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12:878-887.
43. Baratelli F, Takedatsu H, Hazra S, Peebles K, Luo J, Kurimoto PS, Zeng G, Batra RK, Sharma S, Dubinett SM, et al. Pre-clinical characterization ofGMPgrade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. J Transl Med 2008;6:38.
44. Tursz T, Cesne AL, Baldeyrou P, Gautier E, Opolon P, Schatz C, Pavirani A, Courtney M, Lamy D, Ragot T, et al. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst 1996;88:1857-1863.
45. Molinier-Frenkel V, Le Boulaire C, Le Gal FA, Gahery-Segard H, Tursz T, Guillet JG, Farace F. Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients. Hum Gene Ther 2000;11:1911-1920.
46. Griscelli F, Opolon P, Saulnier P, Mami-Chouaib F, Gautier E, Echchakir H, Angevin E, Le Chevalier T, Bataille V, Squiban P, et al. Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Ther 2003;10:386-395.
47. Vansteenkiste J, Canon JL, Riska H, Pirker R, Peterson P, JohnW, Mali P, Lahn M. Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer. Invest New Drugs 2005;23:263-269.
48. Paz-Ares L, Douillard JY, Koralewski P,Manegold C, Smit EF, Reyes JM, Chang GC, John WJ, Peterson PM, Obasaju CK, et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advancedstage non-small-cell lung cancer. J Clin Oncol 2006;24:1428-1434.
49. Cunningham CC, Holmlund JT, Schiller JH, Geary RS, Kwoh TJ, Dorr A, Nemunaitis J. A phase I trial of c-raf kinase antisense oligonucleotide isis 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2000;6:1626-1631.
50. Rudin CM, Holmlund J, Fleming GF, Mani S, Stadler WM, Schumm P, Monia BP, Johnston JF, Geary R, Yu RZ, et al. Phase i trial of isis 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res 2001;7:1214-1220.
51. Stevenson JP, Yao KS, Gallagher M, Friedland D, Mitchell EP, Cassella A, Monia B, Kwoh TJ, Yu R, Holmlund J, et al. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide isis 5132 (cgp 69846a). JClin Oncol 1999;17:2227-2236.
52. Coudert B, Anthoney A, Fiedler W, Droz JP, Dieras V, Borner M, Smyth JF, Morant R, de Vries MJ, Roelvink M, et al. Phase II trial with isis 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer: a European organization for research and treatment of cancer (EORTC) early clinical studies group report. Eur J Cancer 2001;37:2194-2198.
53. Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, Szeto L, Vokes EE. Phase I study of g3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004;22:1110-1117.
54. Rudin CM, Otterson GA, Mauer AM, Villalona-Calero MA, Tomek R, Prange B, George CM, Szeto L, Vokes EE. A pilot trial of g3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002;13:539-545.
55. Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M, Vokes EE. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008;26:870-876.
56. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, et al. Phase ii study of belagenpumatucel-l, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in nonsmall-cell lung cancer. J Clin Oncol 2006;24:4721-4730.
57. Nemunaitis J, Sterman D, Jablons D, Smith JW II, Fox B, Maples P, Hamilton S, Borellini F, Lin A, Morali S, et al. Granulocytemacrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004;96:326-331. (Pubitemid 38256277)
58. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003;21:624-630. (Pubitemid 46621895)
59. Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B, Jablons D, Aimi J, Lin A, Hege K. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 2006;13:555-562.
60. Raez LE, Cassileth PA, Schlesselman JJ, Sridhar K, Padmanabhan S, Fisher EZ, Baldie PA, Podack ER. Allogeneic vaccination with a b7.1 HLA-a gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:2800-2807.
61. Morris JC, Janik JE, Vahanian N, Mertes S, O'Hagan D, Tennant L, Pittaluga S, Albert P, Seregina T, Link C. A phase i study of antitumor vaccination using tumor cells genetically modified to express alpha(1,3)galactosyltransferase (GT) in patients with refractory or recurrent non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24:12503.
62. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Levy E, Krzakowski M, Hess D, Tartour E, Chenard MP, et al. A phase II study of tg4010 (mva-muc1-IL2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol 2008;3:735-744.
63. Nemunaitis J, Meyers T, Senzer N, Cunningham C, West H, Vallieres E, Anthony S, Vukelja S, Berman B, Tully H, et al. Phase I trial of sequential administration of recombinant DNA and adenovirus expressing L523s protein in early stage non-small-cell lung cancer. Mol Ther 2006;13:1185-1191.
64. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006;66:5527-5536.
65. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117:1466-1476.
66. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, et al. Control of large, established tumor xenografts with genetically retargeted human t cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 2009;106:3360-3365.